{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:19:08Z","timestamp":1780377548453,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BRCA1 and BRCA2 play a central role in DNA repair and their germline pathogenic variants (g<jats:italic>BRCA<\/jats:italic>) confer a high risk for developing breast and ovarian cancer. Standard chemotherapy regimens for these cancers include DNA-damaging agents. We hypothesized that <jats:italic>gBRCA<\/jats:italic> carriers might be at higher risk of developing chemotherapy-related hematologic toxicity and therapy-related myeloid neoplasms (t-MN). We conducted a retrospective study of women newly diagnosed with invasive breast or ovarian cancer who were screened for <jats:italic>gBRCA1\/gBRCA2<\/jats:italic> at Geneva University Hospitals. All patients were treated with (neo-)adjuvant chemotherapy. We evaluated acute hematologic toxicities by analyzing the occurrence of febrile neutropenia and severe neutropenia (grade 4) at day 7\u201314 of the first cycle of chemotherapy and G-CSF use during the entire chemotherapy regimen. Characteristics of t-MN were collected. We reviewed medical records from 447 patients: 58 g<jats:italic>BRCA1<\/jats:italic> and 40 gBRCA2 carriers and 349 non-carriers. <jats:italic>gBRCA1<\/jats:italic> carriers were at higher risk of developing severe neutropenia (32% vs. 14.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.007; OR\u2009=\u20093.3, 95% CI [1.6-7], <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and of requiring G-CSF for secondary prophylaxis (58.3% vs. 38.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.011; OR\u2009=\u20092.5, 95% CI [1.4\u20134.8], <jats:italic>p<\/jats:italic>\u2009=\u20090.004). <jats:italic>gBRCA2<\/jats:italic> carriers did not show increased acute hematologic toxicities. t-MN were observed in 2 patients (1 <jats:italic>gBRCA1<\/jats:italic> and one non-carrier). Our results suggested an increased acute hematologic toxicity upon exposure to chemotherapy for breast and ovarian cancer among <jats:italic>gBRCA1<\/jats:italic> but not <jats:italic>gBRCA2<\/jats:italic> carriers. A deeper characterization of t-MN is warranted with the recent development of PARP inhibitors in frontline therapy in <jats:italic>gBRCA<\/jats:italic> breast and ovarian cancer.<\/jats:p>","DOI":"10.1007\/s10689-023-00331-6","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T06:02:14Z","timestamp":1682748134000},"page":"283-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1\/BRCA2 germline pathogenic variants. A single center experience and review of the literature"],"prefix":"10.1007","volume":"22","author":[{"given":"Ketty","family":"Hu-Heimgartner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Ayme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2011Damien","family":"Combes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor N.","family":"Chappuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Friedlaender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Vuilleumier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bodmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Viassolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre O.","family":"Chappuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Intidhar","family":"Labidi-Galy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"issue":"1","key":"331_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2012","unstructured":"Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12(1):68\u201378","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"331_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812\u2013822","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"331_CR3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ et al (2017) Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"10","key":"331_CR4","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/0008-5472.CAN-13-2611","volume":"74","author":"KI Savage","year":"2014","unstructured":"Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ et al (2014) BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res 74(10):2773\u20132784","journal-title":"Cancer Res"},{"issue":"45","key":"331_CR5","doi-asserted-by":"publisher","first-page":"E10642","DOI":"10.1073\/pnas.1803177115","volume":"115","author":"H Sasanuma","year":"2018","unstructured":"Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y et al (2018) BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc Natl Acad Sci U S A 115(45):E10642\u2013E51","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"331_CR6","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1186\/s12885-020-07524-7","volume":"20","author":"L Song","year":"2020","unstructured":"Song L, Tang Z, Peng C, Yang Y, Guo C, Wang D et al (2020) Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium. BMC Cancer 20(1):1020","journal-title":"BMC Cancer"},{"issue":"3","key":"331_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199","journal-title":"Crit Rev Oncol Hematol"},{"key":"331_CR8","unstructured":"NCI. Common Terminology Criteria for Adverse Events V4.0 2010 [Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html"},{"issue":"18","key":"331_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","volume":"328","author":"PA Pizzo","year":"1993","unstructured":"Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328(18):1323\u20131332","journal-title":"N Engl J Med"},{"issue":"1","key":"331_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"key":"331_CR11","doi-asserted-by":"crossref","unstructured":"Deshpande M, Paniza T, Jalloul N, Nanjangud G, Twarowski J, Koren A et al (2022) Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells.Mol Cell.","DOI":"10.1016\/j.molcel.2022.08.017"},{"issue":"1","key":"331_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","volume":"8","author":"KN Maxwell","year":"2017","unstructured":"Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L et al (2017) BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun 8(1):319","journal-title":"Nat Commun"},{"issue":"4","key":"331_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.celrep.2016.12.075","volume":"18","author":"VE Mgbemena","year":"2017","unstructured":"Mgbemena VE, Signer RAJ, Wijayatunge R, Laxson T, Morrison SJ, Ross TS (2017) Distinct Brca1 mutations differentially reduce hematopoietic stem cell function. Cell Rep 18(4):947\u2013960","journal-title":"Cell Rep"},{"key":"331_CR14","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1038\/ncomms8505","volume":"6","author":"M Sedic","year":"2015","unstructured":"Sedic M, Skibinski A, Brown N, Gallardo M, Mulligan P, Martinez P et al (2015) Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun 6:7505","journal-title":"Nat Commun"},{"key":"331_CR15","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1038\/ncomms6496","volume":"5","author":"S Pathania","year":"2014","unstructured":"Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C et al (2014) BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun 5:5496","journal-title":"Nat Commun"},{"issue":"43","key":"331_CR16","doi-asserted-by":"publisher","first-page":"17773","DOI":"10.1073\/pnas.1110969108","volume":"108","author":"H Konishi","year":"2011","unstructured":"Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S et al (2011) Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A 108(43):17773\u201317778","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"331_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10549-018-05127-2","volume":"174","author":"A Friedlaender","year":"2019","unstructured":"Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD et al (2019) BRCA1\/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. Breast Cancer Res Treat 174(3):775\u2013783","journal-title":"Breast Cancer Res Treat"},{"key":"331_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejca.2020.12.007","volume":"145","author":"J Furlanetto","year":"2021","unstructured":"Furlanetto J, Mobus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU et al (2021) Germline BRCA1\/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 145:44\u201352","journal-title":"Eur J Cancer"},{"issue":"2","key":"331_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ygyno.2021.01.037","volume":"161","author":"J Gillen","year":"2021","unstructured":"Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA et al (2021) Post hoc analyses of GOG 9923: does BRCA status affect toxicities?: an NRG oncology study. Gynecol Oncol 161(2):512\u2013515","journal-title":"Gynecol Oncol"},{"issue":"2","key":"331_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ygyno.2021.12.012","volume":"164","author":"C Aghajanian","year":"2022","unstructured":"Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF et al (2022) Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol 164(2):278\u2013287","journal-title":"Gynecol Oncol"},{"issue":"5","key":"331_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM et al (2021) Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 22(5):620\u2013631","journal-title":"Lancet Oncol"},{"issue":"2","key":"331_CR22","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","volume":"8","author":"PM Morice","year":"2021","unstructured":"Morice PM, Leary A, Dolladille C, Chretien B, Poulain L, Gonzalez-Martin A et al (2021) Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol 8(2):e122\u2013e34","journal-title":"Lancet Haematol"},{"issue":"2","key":"331_CR23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","volume":"159","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Benigno B, Dorum A, Mahner S, Bessette P, Barcelo IB et al (2020) Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16\/NOVA trial. Gynecol Oncol 159(2):442\u2013448","journal-title":"Gynecol Oncol"},{"issue":"12","key":"331_CR24","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1001\/jamaoncol.2021.4664","volume":"7","author":"TT Kwan","year":"2021","unstructured":"Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Aghajanian C et al (2021) Preexisting TP53-Variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian Cancer treated with Rucaparib. JAMA Oncol 7(12):1772\u20131781","journal-title":"JAMA Oncol"},{"key":"331_CR25","doi-asserted-by":"crossref","unstructured":"Incorvaia L, Fiorino A, Gori S, Cinieri S, Curigliano G, Toss A et al (eds) (2022) Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD). ESMO annual meeting; ; Paris, France","DOI":"10.1016\/j.annonc.2022.07.1030"},{"key":"331_CR26","doi-asserted-by":"publisher","first-page":"175883592110596","DOI":"10.1177\/17588359211059601","volume":"13","author":"JP Ayoub","year":"2021","unstructured":"Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S et al (2021) Safety and efficacy of veliparib plus carboplatin\/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1\/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. Ther Adv Med Oncol 13:17588359211059601","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"331_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrc3088","volume":"11","author":"AJ Deans","year":"2011","unstructured":"Deans AJ, West SC (2011) DNA interstrand crosslink repair and cancer. Nat Rev Cancer 11(7):467\u2013480","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"331_CR28","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M et al (2018) Maintenance Olaparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med 379(26):2495\u20132505","journal-title":"N Engl J Med"},{"issue":"25","key":"331_CR29","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-Mutated breast Cancer. N Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"25","key":"331_CR30","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R et al (2019) Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med 381(25):2416\u20132428","journal-title":"N Engl J Med"},{"key":"331_CR31","doi-asserted-by":"crossref","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A et al (2022) Overall survival with maintenance olaparib at a 7-Year Follow-Up in patients with newly diagnosed Advanced Ovarian Cancer and a BRCA mutation: the SOLO1\/GOG 3004 Trial.J Clin Oncol. :JCO2201549","DOI":"10.1097\/OGX.0000000000001120"},{"key":"331_CR32","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L et al (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high risk, early breast cancer.Ann Oncol."},{"issue":"5","key":"331_CR33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cncr.31144","volume":"124","author":"AS Rosenstock","year":"2018","unstructured":"Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez-MacGregor M (2018) Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: a population-based study among older breast cancer patients. Cancer 124(5):899\u2013906","journal-title":"Cancer"},{"issue":"2","key":"331_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-016-4051-1","volume":"161","author":"RA Freedman","year":"2017","unstructured":"Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG et al (2017) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group trials (Alliance A151511). Breast Cancer Res Treat 161(2):363\u2013373","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"331_CR35","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/bjc.2016.58","volume":"114","author":"J Iqbal","year":"2016","unstructured":"Iqbal J, Nussenzweig A, Lubinski J, Byrski T, Eisen A, Bordeleau L et al (2016) The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Br J Cancer 114(10):1160\u20131164","journal-title":"Br J Cancer"},{"issue":"2","key":"331_CR36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cncr.29615","volume":"122","author":"JE Churpek","year":"2016","unstructured":"Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM et al (2016) Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer 122(2):304\u2013311","journal-title":"Cancer"},{"issue":"7540","key":"331_CR37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518(7540):552\u2013555","journal-title":"Nature"},{"issue":"11","key":"331_CR38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D et al (2020) Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 52(11):1219\u20131226","journal-title":"Nat Genet"},{"issue":"8","key":"331_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.annonc.2021.04.015","volume":"32","author":"JE Martin","year":"2021","unstructured":"Martin JE, Khalife-Hachem S, Grinda T, Kfoury M, Garciaz S, Pasquier F et al (2021) Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. Ann Oncol 32(8):1046\u20131048","journal-title":"Ann Oncol"},{"issue":"2","key":"331_CR40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV et al (2019) BRCA reversion mutations in circulating tumor DNA predict primary and Acquired Resistance to the PARP inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 9(2):210\u2013219","journal-title":"Cancer Discov"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-023-00331-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-023-00331-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-023-00331-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T04:26:32Z","timestamp":1686889592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-023-00331-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["331"],"URL":"https:\/\/doi.org\/10.1007\/s10689-023-00331-6","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}